Flaharty Asset Management’s AstraZeneca AZN Stock Holding History

Flaharty Asset Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-5,991	Closed	-$1.18M	–	59
2026 Q1	$1.18M	Sell	5,991 -1	-0%	-$193	0.15%	52
2025 Q4	$1.1M	Sell	5,992 -58	-1%	-$10.2K	0.14%	58
2025 Q3	$928K	Hold	6,050	–	–	0.12%	52
2025 Q2	$845K	Hold	6,050	–	–	0.12%	53
2025 Q1	$889K	Hold	6,050	–	–	0.13%	51
2024 Q4	$793K	Hold	6,050	–	–	0.12%	55
2024 Q3	$943K	Hold	6,050	–	–	0.13%	52
2024 Q2	$944K	Hold	6,050	–	–	0.14%	51
2024 Q1	$820K	Hold	6,050	–	–	0.12%	57
2023 Q4	$815K	Hold	6,050	–	–	0.13%	53
2023 Q3	$819K	Hold	6,050	–	–	0.14%	51
2023 Q2	$866K	Hold	6,050	–	–	0.15%	50
2023 Q1	$840K	Sell	6,050 -12	-0.2%	-$1.61K	0.15%	47
2022 Q4	$822K	Hold	6,062	–	–	0.15%	51
2022 Q3	$665K	Sell	6,062 -55	-0.9%	-$6.98K	0.14%	57
2022 Q2	$808K	Buy	6,117 +2,822	+86%	+$370K	0.16%	48
2022 Q1	$437K	Hold	3,295	–	–	0.08%	73
2021 Q4	$384K	Buy	3,295 +55	+2%	+$6.47K	0.07%	82
2021 Q3	$389K	Buy	+3,240	New	+$377K	0.08%	77

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Flaharty Asset Management's AZN Position: Q2 2026 in Review

Flaharty Asset Management sold out of AstraZeneca (AZN) in Q2 2026, closing a stake of 5,991 shares — an estimated $1.18M sold.

Flaharty Asset Management first reported a position in AZN in Q3 2021 and held it in 19 quarters. The position peaked at $1.18M in Q1 2026. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Flaharty Asset Management reported no remaining AstraZeneca position as of Q2 2026 after selling out during the quarter.
Flaharty Asset Management sold 5,991 AstraZeneca shares in Q2 2026, an estimated $1.18M.
Flaharty Asset Management first reported a position in AstraZeneca in Q3 2021 and held it in 19 quarters.
Flaharty Asset Management's AstraZeneca position peaked at $1.18M in Q1 2026.
1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Flaharty Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.